Maria Viskadourou

Maria Viskadourou

Auto-generated profile, based on publicly available information

Maria Viskadourou

Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD (P.R., P.T.-S., M.D.-M., M.V., D.B.F., N.A., C.G.-C., W.O.O., M.A.).

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2026 in Circulation Research
Verified
Journal Article
Closed access
MVMaria Viskadourou
Maria Viskadourou
SCSharjeel Chaudhry
Sharjeel Chaudhry
ASArianna Scalco
Arianna Scalco
PRPaula Reventun
Paula Reventun
PTPablo Toledano-Sanz
Pablo Toledano-Sanz
MAMarios Arvanitis
Marios Arvanitis
BACKGROUND: Genome-wide association studies have identified multiple novel loci that contribute to coronary artery disease pathogenesis, but the mechanisms of these associations remain largely unknown. METHODS: In this study, we used a multitrait colocalization approach to prioritize novel endothelial-specific loci for atherosclerosis. We combined computational methods with in vitro assays and mouse models to study one of those new loci targeting the gene REST (RE1-silencing transcription factor). RESULTS: A multitrait colocalization approach across expression quantitative trait loci in atherosclerosis-relevant cell types, followed by in vitro CRISPR interference, revealed that a conserved regulatory element in a chromosome 4 genetic locus increases the risk of coronary artery disease and decreases the expression of REST, a transcriptional repressor, in endothelial cells. Pcsk9 -overexpressing mice with an endothelial-specific knockout of Rest exhibited increased atherosclerotic plaque formation in their aortas, with increased macrophage and lipid deposition within the plaque after 16 weeks of high-fat diet exposure compared with littermate controls. RNA-seq in human aortic endothelial cells after REST silencing, followed by assessment of protein expression, revealed that REST silencing triggers endothelial-to-mesenchymal transition. Consistently, REST silencing increased endothelial permeability and migration in vitro. Single-nucleus RNA sequencing in endothelial lineage traced atherosclerotic mice with Rest knock-out revealed evidence of endothelial TGFb signaling activation and of transition smooth muscle-like cells in atherosclerotic aortas on genetic knockout of Rest . Cleavage under targets and tagmentation (CUT&Tag) sequencing did not identify any known TGFb (transforming growth factor-beta) effector genes as direct REST transcriptional targets. Instead, joint analysis of CUT&Tag with RNA-seq highlighted L1CAM (L1 cell adhesion molecule), a known endothelial-to-mesenchymal transition activator, and its interactors as the most significant gene set directly affected by REST in the endothelium. Simultaneous silencing of L1CAM and REST in human aortic endothelial cells inhibited the upregulation of mesenchymal genes and the enhanced migration induced by REST silencing and diminished the upregulation of several TGFb effectors overexpressed on REST silencing. CONCLUSIONS: In summary, our data reveal the novel role of REST as a repressor in endothelial cells that functions to constitutively inhibit endothelial-to-mesenchymal transition and protect against atherosclerosis.

1 March 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PRPaula Reventun
Paula Reventun
PTPablo Toledano-Sanz
Pablo Toledano-Sanz
MDMaría Delgado-Marin
María Delgado-Marin
MVMaria Viskadourou
Maria Viskadourou
DFD. Brian Brian Foster
D. Brian Brian Foster
CLCharles J. Lowenstein
Charles J. Lowenstein
BACKGROUND: Abnormal levels of VWF (von Willebrand Factor) are a risk factor for venous thromboembolism (VTE) and bleeding. Genome-wide association studies for VWF have identified novel candidate genes that may regulate VWF levels in humans, including RAB5C (RAS [rat sarcoma]-associated protein RAB5C). We hypothesized that RAB5C regulates VWF release from endothelial cells. METHODS: We studied the effect of RAB5C on vesicle trafficking in human endothelial cells. We performed CRISPR (clustered regularly interspaced short palindromic repeats) interference targeting 2 genetic variants linked to altered VWF levels and evaluated RAB5C expression by reverse transcription–quantitative polymerase chain reaction. We silenced RAB5C or overexpressed RAB5C wild-type, constitutive active or dominant negative; and then, we measured VWF exocytosis from human umbilical vein endothelial cells to the media by ELISA. We performed proximity labeling and mass spectrometry to identify intracellular signaling pathways mediating the effects of RAB5C on VWF exocytosis. RESULTS: We found that 2 genetic variants (rs9915255 and rs9912088 identified by genome-wide association studies for VWF levels) regulate RAB5C expression in stem cell–derived endothelial cells. We next silenced or overexpressed RAB5C in endothelial cells to assess its effect on VWF release. RAB5C silencing decreased VWF release after histamine stimulation, whereas overexpression of RAB5C or constitutively active RAB5C increased endothelial VWF release. To explore the intracellular signaling pathway mediating the effects of RAB5C on VWF exocytosis, we performed proximity labeling and mass spectrometry. We identified 147 proteins proximal to RAB5C, many of which are involved in vesicle trafficking. From this screen, we identified SNAP29 (synaptosome-associated protein 29), a SNARE (soluble NSF [N-ethylmaleimide-sensitive factor] attachment receptor)-associated protein that plays a crucial role in vesicle fusion, as a key RAB5C interactor regulating VWF exocytosis. CONCLUSIONS: Taken together, our data demonstrate that RAB5C regulates VWF release in part through SNAP29 control of vesicle trafficking in endothelial cells. These findings validate genetic epidemiology data linking RAB5C to VWF levels in humans and provide new insights into the molecular mechanisms regulating VWF exocytosis.